AbbVie Inc (ABBV)vsGinkgo Bioworks Holdings (DNA)
ABBV
AbbVie Inc
$294.48
-0.18%
HEALTHCARE · Cap: $521.11B
DNA
Ginkgo Bioworks Holdings
$10.23
-0.20%
HEALTHCARE · Cap: $754.88M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 49752% more annual revenue ($66.01B vs $132.42M). ABBV leads profitability with a 15.7% profit margin vs -219.6%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
DNA
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$294.48
$137.19 premium
Margin of Safety
-27.7%
Fair Value
$7.32
Current Price
$10.23
$2.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : DNA
The strongest argument for DNA centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : DNA
The primary concerns for DNA are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
ABBV profiles as a mature stock while DNA is a turnaround play — different risk/reward profiles.
DNA carries more volatility with a beta of 1.79 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 28/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Ginkgo Bioworks Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide range of sectors, including pharmaceuticals, agriculture, and industrial biotechnology. The company's innovative platform streamlines cellular design and manufacturing, positioning Ginkgo as a key player in addressing critical global challenges such as climate change and food security. With a strong focus on sustainable biotechnology solutions, Ginkgo is well-equipped to tap into the increasing market demand for bio-based alternatives, highlighting its potential for significant growth and transformative impact across various industries.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?